Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648739 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00648739 is a Phase 1 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT00648739, a Phase 1 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) and to study how samalizumab may help the immune system fight tumors that express CD200.
Interventions
- DRUG Samalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-06-19 |
| Est. Completion | 2010-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648739
The ClinicalTrials.gov registry entry for NCT00648739 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Samalizumab is the first listed.
NCT00648739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648739 about?
NCT00648739 is a clinical study titled "Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM". The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) and to study how samalizumab may help the immune system fight tumors that express ...
What is the current status of trial NCT00648739?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-06-19. Estimated completion is 2010-12-14.
What interventions are being tested in trial NCT00648739?
The interventions under investigation include: Samalizumab (DRUG).
Who is sponsoring clinical trial NCT00648739?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.